&lt;sup&gt;177&lt;/sup&gt;Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Novartis Pharmaceuticals
Michael J Morris; Daniel Castellano; Ken Herrmann; Johann S de Bono; Neal D Shore; Kim N Chi; Michael Crosby; Josep M Piulats; Aude Fléchon; Xiao X Wei; Hakim Mahammedi; Guilhem Roubaud; Hana Študentová; James Nagarajah; Begoña Mellado; Álvaro Montesa-Pino; Euloge Kpamegan; Samson Ghebremariam; Teri N Kreisl; Celine Wilke; Katja Lehnhoff; Oliver Sartor; Karim Fizazi; PSMAfore Investigators